Clinical and Translational Science Awards (CTSA) Program hub researchers at the University of New Mexico (UNM), University of Kansas Medical Center (KUMC), and University of North Carolina (UNC), Chapel Hill, are collaborating to more rapidly test existing drugs and advance those showing promise into clinical trials. The Drug Rescue, Repurposing and Repositioning Network (DR3N), led by UNM Principal Investigator Richard Larson, M.D., Ph.D., and component leader Larry Sklar, Ph.D., provides CTSA Program investigators with access to state-of-the-art technology, innovative tools, and guidance in translating pilot projects from preclinical to clinical stages via drug repurposing.
Each DR3N hub offers unique drug-discovery expertise, resources and capabilities. UNM has drug libraries, high-throughput small-molecule screening and analytic capabilities; KUMC specializes in chemistry and formulation; and UNC offers a number of specialized receptor assays and libraries. DR3N launched last year, and several early-stage projects — both within the network institutions and with outside hubs — are already underway. Through this integrated, collaborative network, the investigators aim to accelerate drug discovery to bring more treatments to more patients more quickly.
Posted February 2016